Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.59 |
| ▸ | CA2 | P00918 | 18/20 | 0.59 |
| ▸ | CA12 | O43570 | 13/20 | 0.59 |
| ▸ | CA9 | Q16790 | 12/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 4/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28827412 | 0.85 | CA1 (0.41) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL10880984 | 0.83 | CA12 (0.44) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL28201480 | 0.78 | CA1 (0.61) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL12332592 | 0.77 | CA1 (0.75) | CA1CA2CA12CA9CA7 | |
| SCHEMBL33651 | 0.77 | MAPT (0.41) | KMT2AALDH1A1HPGD | |
| SCHEMBL27887792 | 0.76 | CA1 (0.45) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL28513477 | 0.75 | CA2 (0.58) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL27540686 | 0.75 | CA2 (0.62) | CA1CA2CA12CA9KMT2A | |
| Sulfanilamide SCHEMBL27887793 | 0.75 | CA2 (0.65) | CA1CA2CA12CA9CA7 | |
| SCHEMBL27936984 | 0.74 | CA2 (0.67) | CA1CA2CA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212296-B9 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1212296-B1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN INC (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1392643-B1 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LAB (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6831193-B2 | Treating pain, urinary incontinence and bladder overactivity; P2X receptors are cation-permeable ion channels | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20040138255-A1 | Phosphate mimics and methods of treatment using phosphatease inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
| US-6596772-B1 | Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are | SUGEN, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| EP-1212296-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016097-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138255-A1 | Phosphate mimics and methods of treatment using phosphatease inhibitors | PPP4C, PTPRO, PTPRS | CA1 833/4885CA2 283/4885CA12 2513/4885 |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | CA1 2300/4885CA2 380/4885CA12 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.